Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mustang Leads Fortress's CAR-T Ambitions Of Monstrous Proportions

Executive Summary

Emerging Company Profile: The two-year-old company combines the Fortress Biotech model with City of Hope's broad expertise in CAR-T technology, plus leadership from a pioneer in the space.

Advertisement

Related Content

Tech Transfer Roundup: Mustang Licenses St. Jude’s Gene Therapy For Bubble Boy Disease
Tech Transfer Roundup: Mustang, Juno Advance Efforts With Immuno-Oncology
IPO Update: New Filings Feed Investor Fervor As Biopharma Stocks Rise
Novartis' CAR-T Poised For The Market After Unanimous FDA Adcomm Review
Fortress Biotech: A Drug Financing Experiment Expands
Appointments: Bayer, Mustang, Modus, GammaDelta, Poxel, Metrion and Renova.

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC099152

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel